ALK and lung carcinoma: Brigatinib is approved for the treatment of adult patients with ALK-positive metastatic NSCLC based on the results of the phase 2 ALK in Lung Cancer Trial of BrigAtinib (ALTA) (NCT02094573) [4, 5] and the phase 3 ALTA in 1st Line study (ALTA-1L) (NCT02737501) [6].